Analysis of clinical characteristics of patients with TB-damaged pulmonary hypertension

doi:10.19871/j.cnki.xfcrbzz.2025.02.008

Abstract

Abstract: Objective To analyze the laboratory tests, imaging, echocardiography and hemodynamic characteristics of pulmonary hypertension (PH) associated with tuberculous lung destruction, and to provide clinical evidence for the diagnosis and treatment of such patients. Method A retrospective collection was made of 44 patients with PH associated with tuberculous lung destruction who were hospitalized at Chongqing Public Health Medical Treatment Center from July 1, 2023 to June 30, 2024. Basic demographic information, the extent of lung destruction, laboratory tests, imaging, echocardiography and right heart catheterization data of the patients were collected, and the clinical characteristics of the patients were analyzed. Result The age of patients with PH associated with tuberculous lung destruction was (56.64±11.10) years, and the body mass index (BMI) was (17.95±2.87)kg/m². The proportion of male patients was 2.1 times that of female patients. D-dimer was 1.06 (0.42, 2.02)mg/L, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) was 453.00(191.00,1178.00)pg/ml. The left lung was the most frequently involved site of destruction (54.55%). Bronchiectasis was present in 29 cases (65.91%), and pulmonary cavities in 23 cases (52.27%). Pleural thickening was present in 43 cases (97.73%). The estimated pulmonary artery systolic pressure by echocardiography was 53.0 (40.25, 60.75) mmHg. The diameter of the main pulmonary artery was wider in female patients than in male patients (P<0.05). The mean pulmonary artery pressure (mPAP) of the 12 patients who underwent right heart catheterization was 31.00 (29.00, 35.25) mmHg, and the pulmonary vascular resistance (PVR) was 6.02 (3.87, 8.91) WU. Conclusion Patients with PH associated with tuberculous lung destruction have a low BMI level, a higher proportion of male patients than female patients, elevated D-dimer and NT-proBNP, and the destruction often involves the left lung. They also have multiple lung destructions, and hemodynamic indicators suggest a significant increase in PVR.

Key words: Tuberculosis, Destroyed lung, Pulmonary hypertension, Clinical characteristics

CLC Number:

Sun Nannan, Xiong Yanmei, Yang Song, Cen Wuqiang, Liu Xueyan. Analysis of clinical characteristics of patients with TB-damaged pulmonary hypertension[J]. Electronic Journal of Emerging Infectious Diseases, 2025, 10(2): 40-46.

References

[1] 李媛媛, 谢晶晶, 李树涛,等. 2024年WHO全球结核病报告:全球与中国关键数据分析[J/CD]. 新发传染病电子杂志, 2024, 9(6):92-97.
[2] KIM HY, SONG KS, GOO JM, et al.Thoracic sequelae and complications of tuberculosis[J]. Radiographics, 2001, 21(4):839-858.
[3] PASIPANODYA JG, MILLER TL, VECINO M, et al.Lung damage after pulmonary tuberculosis[J]. The chest, 2007, 131:1817-1824.
[4] ALLWOOD BW, BYRNE A, MEGHJI J, et al.Post-tuberculosis lung disease: clinical review of anunder-recognised global challenge[J]. Respiration, 2021, 100(8):751-763.
[5] VISCA D, CENTIS R, MUNOZ-TORRICO M, et al.Post tuberculosis sequelae: the need to look beyond treatment outcome[J]. Int J Tuberc Lung Dis, 2020, 24(8):761-762.
[6] LIU W, XU Y, YANG L, et al.Risk factors associated with pulmonary hypertension in patients with active tuberculosis and tuberculous destroyed lung: a retrospective study[J]. Sci Rep, 2024, 14(1):10108.
[7] 曾坚, 王瑾, 方木通, 等.结核后慢性肺曲霉病患者的临床特征及影响因素分析[J/CD]. 新发传染病电子杂志, 2024, 9(5):25-30.
[8] 韩倩, 马礼兵. 慢性阻塞性肺疾病共患病研究进展[J]. 国际呼吸杂志, 2021, 41(19):1441-1445.
[9] POOR HD,KAWUT SM,LIU CY,et al.Pulmonary hyperinflation due to gastrapping and pulmonary artery size:The MESA COPD Study[J]. PLoS One, 2017, 12(5):e0176812.
[10] NATHAN SD, BARBERA JA, GAINE SP, et al.Pulmonary hypertension in chronic lung disease and hypoxia[J]. Eur Respir J, 2019, 53(1):1801914.
[11] KIM CJ,YOON HK,PARK MJ,et al.Inhaled indacaterol for the treatment of COPD patients with detroyed lung by tuberculosis and moderate-to-severe airflow limitation:results form the randomised INFINITY study[J]. Int J Chron Obstruct Pulmon Dis, 2017, 12:1589-1596.
[12] 中华医学会呼吸病学会肺栓塞与肺血管病学,中国肺动脉高血压诊断与治疗指南(2021版)[J]. 中华医学杂志,2021,101(1):11-51.
[13] EOM JS,PARK HY,LEE MK,et al. The effects of bronchodilators in patients with tuberculosis-destroyed lung and chronic airflow obstruction[J]. Eur Respir J, 2015, 46(Suppl 59):PA3941.
[14] SEEGER W, ADIR Y, BARBERA JA, et al.Pulmonary arterial hypertension in chronic lung disease[J]. J Am Coll Cardiol, 2013, 62(25 Suppl):D109-116.
[15] CASTRIA D,REFINI RM,BARGAGLI E,et al.Pulmonary hypertension in idiopathic pulmonary fibrosis:prevalence and clinical progression[J].Int J Immunopathol Pharmacol, 2012, 25:681-689.
[16] MANDRAS SA, MEHTA HS, VAIDYA A.Pulmonary Hypertension: A Brief Guide for Clinicians[J]. Mayo Clin Proc, 2020, 95(9):1978-1988.
[17] 国家心血管病中心肺动脉高压专科联盟国家, 心血管病专家委员会右心与肺血管病专业委员会. 中国肺动脉高压诊治临床路径[J]. 中国循环杂志, 2023, 38(7):691-703.
[18] 中华医学会放射学分会传染病放射学组,中国医师协会放射医师分会感染影像专业委员会,中国研究型医院学会感染与炎症放射专业委员会, 等. 肺结核影像诊断标准[J/CD]. 新发传染病电子杂志, 2021, 6(1):1-6.
[19] 方伟军, 何玉麟, 许传军, 等.《肺结核影像诊断标准》解读[J/CD]. 新发传染病电子杂志, 2021, 6(1):73-78.
[20] JO YS, PARK JH, LEE JK, et al.Risk factors for pulmonary arterial hypertension in patients with tuberculosis-destroyed lungs and their clinical characteristics compared with patients with chronic obstructive pulmonary disease[J]. Int J Chron Obstruct Pulmon Dis, 2017, 12:2433-2443.
[21] HOEPER MM, HUMBERT M, SOUZA R, et al.A global view of pulmonary hypertension[J]. Lancet Respir Med, 2016, 4(4):306-322.
[22] LIN HH, EZZATI M, CHANG HY, et al.Association between tobacco smoking and active tuberculosis in Taiwan:prospective cohort study[J]. Am J Respir Crit Care Med, 2009, 180(5):475-480.
[23] BAGCCHI S.WHO's Global Tuberculosis Report 2022[J]. Lancet Microbe, 2023, 4(1):e20.
[24] FRITZ JS, BLAIR C, OUDIZ RJ, et al.Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension[J].Chest,2013,143(2):315-323.
[25] PAILIN R, ANDREA O, CALEB RJ, et al.Performance of pulmonary artery dimensions measured on high-resolution computed to mography scan for identifying pulmonary hypertension[J]. ER J open research, 2020, 6(1):00232-00241.
[26] ARCASOY SM, CHRISTIE JD, FERRARI VA, et al.Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease[J]. Am J Respir Crit Care Med, 2003, 167(5):735-740.
[27] HUMBERT M, KOVACS G, HOEPER MM, et al.2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Eur Respir J, 2023, 61(1):3618-3731.
[28] PAILIN R, ANDREA O, CALEB RJ, et al.Performance of pulmonary artery dimensions measured on high-resolution computed to mography scan for identifying pulmonary hypertension[J]. ER J open research, 2020, 6(1):00232-00241.
[29] CHERON C, MCBRIDE SA, ANTIGNY F, et al.Sex and gender in pulmonary arterial hypertension[J]. Eur Respir Rev, 2021, 30(162):200330.
[30] KOSIF MISIRLIOGLU A, BAYRAM S, KIRAL H, et al.Factors affecting complication rates of pneumonectomy in destroyed lung[J]. Turk Gogus Kalp Damar Cerrahisi Derg, 2018, 26(2):272-278.
[31] JO YS, PARK JH, LEE JK, et al.Risk factors for pulmonary arterial hypertension in patients with tuberculosis-destroyed lungs and their clinical characteristics compared with patients with chronic obstructive pulmonary disease[J]. Int J Chron Obstruct Pulmon Dis, 2017, 12:2433-2443.
[32] STEINER MK, SYRKINA OL, KOLLIPUTI N, et al.Overexpression of interleukin-6 induces pulmonary arterial hypertension[J]. Circ Res, 2009, 104(2):236-244.
[33] ZANGIABADI A, DE PASQUALE CG, SAJKOV D.Pulmonary arterial hypertension and right heart dysfunction in chronic lung diseases[J]. Biomed Res Int, 2014, 2014:739674.
[34] HURDMAN J, CONDLIFFE R, ELLIOT CA, et al.Pulmonary arterial hypertension in COPD: Results from Aspire Registry[J]. EUR RESSIR J, 2013,41(6):1292-1301.
[35] TIWARI V, WAGH P.Left-Sided Destroyed Lung With Severe Pulmonary Arterial Hypertension as a Consequence of Recurrent Pulmonary Tuberculosis[J]. Cureus, 2024, 16(3):e56870.
[36] MAYEUX JD, PAN IZ, DECHAND J, et al.Management of pulmonary arterial hypertension[J]. Curr Cardiovasc Risk Representative, 2021, 15(1):2.